Overview
Conception.bio develops fertility treatments by turning a person’s blood cells into mature egg cells using induced pluripotent stem cell (iPSC) technology. Blood is collected, reprogrammed into iPSCs, and guided to become viable eggs that can be used for reproduction, with optional genetic screening of embryos. It differentiates itself by producing patient-derived eggs from blood and selling directly to consumers, bypassing traditional clinic pathways. The goal is to broaden access to fertility options by enabling later-life parenting and embryo genetic screening through a patient-derived egg platform with a direct-to-consumer model.
Work here?Claim your company
Simplify's Take
What believers are saying
- June 2026 milestone brought major press and validated technical traction after years of secrecy.
- Senior-scientist hiring in May 2026 signals continued team-building around 3D organoid development.
- Conception still claims a broad fertility market: infertility, age-related decline, and same-sex parenthood.
What critics are saying
- Conception itself says clinical trials remain years away, with safety thresholds still unmet.
- Lancaster University and Nuffield highlighted unresolved consent, parenthood, and child-rights issues in 2025.
- U.S. and European regulators can block IVG commercialization for years, starving Conception before revenue.
What makes Conception unique
- Conception generated stem-cell-derived primary oocytes in June 2026, not just embryo models.
- Its blood-draw-to-mini-ovary workflow targets patient-specific eggs from iPSCs, unlike donor-egg clinics.
- Few competitors pursue human in vitro gametogenesis with a direct-to-consumer fertility model.
Help us improve and share your feedback! Did you find this helpful?